Coronary artery disease in decompensated patients undergoing liver transplantation evaluation

Samarth S. Patel, Eiman Nabi, Luis Guzman, Antonio Abbate, Chandra Bhati, Richard T. Stravitz, Trevor Reichman, Scott C. Matherly, Carolyn Driscoll, Hannah Lee, Velimir A. Luketic, Richard K. Sterling, Arun J. Sanyal, Vaishali Patel, Marlon Levy, Mohammad Shadab Siddiqui – 12 January 2018 – Coronary artery disease (CAD) is an important contributor to morbidity and mortality in patients undergoing liver transplantation (LT). However, the current literature is limited by sampling bias and nondefinitive assessment of CAD.

Improved portal vein venoplasty with an autogenous patch in pediatric living donor liver transplantation

Mingxuan Feng, Ping Wan, Bijun Qiu, Tao Zhou, Yi Luo, Lihong Gu, Jiachang Chi, Chengpeng Zhong, Yefeng Lu, Jianjun Zhang, Qiang Xia – 12 January 2018 – A stenotic or hypoplastic portal vein (PV) represents a challenge for PV reconstruction in pediatric living donor liver transplantation (LDLT). Several PV venoplastic techniques have been developed. However, we still seek improved venoplastic techniques with better efficacy and compatibility. From June 2016 to July 2017, 271 LDLT procedures were performed at the Department of Liver Surgery, Renji Hospital.

Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage‐refractory itch

Robert Holz, Andreas E. Kremer, Dieter Lütjohann, Hermann E. Wasmuth, Frank Lammert, Marcin Krawczyk – 10 January 2018 – Benign recurrent intrahepatic cholestasis (BRIC) is a peculiar familial disease caused by mutations of the genes encoding hepatocanalicular flippase for phosphatidylserine (ATP8B1; BRIC type 1) or the bile salt export pump (ABCB11; BRIC type 2). Here, we report on a patient with nasobiliary drainage‐refractory BRIC type 2 who improved under plasma separation and anion absorption therapy.

Offer acceptance practices and geographic variability in allocation model for end‐stage liver disease at transplant

Andrew Wey, Joshua Pyke, David P. Schladt, Sommer E. Gentry, Tim Weaver, Nicholas Salkowski, Bertram L. Kasiske, Ajay K. Israni, Jon J. Snyder – 9 January 2018 – Offer acceptance practices may cause geographic variability in allocation Model for End‐Stage Liver Disease (aMELD) score at transplant and could magnify the effect of donor supply and demand on aMELD variability.

Single‐cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma

Hongping Zheng, Yotsawat Pomyen, Maria Olga Hernandez, Caiyi Li, Ferenc Livak, Wei Tang, Hien Dang, Tim F. Greten, Jeremy L. Davis, Yongmei Zhao, Monika Mehta, Yelena Levin, Jyoti Shetty, Bao Tran, Anuradha Budhu, Xin Wei Wang – 9 January 2018 – Intratumor molecular heterogeneity of hepatocellular carcinoma is partly attributed to the presence of hepatic cancer stem cells (CSCs). Different CSC populations defined by various cell surface markers may contain different oncogenic drivers, posing a challenge in defining molecularly targeted therapeutics.

Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity

Yuli Cai, Honggui Li, Mengyang Liu, Ya Pei, Juan Zheng, Jing Zhou, Xianjun Luo, Wenya Huang, Linqiang Ma, Qiuhua Yang, Shaodong Guo, Xiaoqiu Xiao, Qifu Li, Tianshu Zeng, Fanyin Meng, Heather Francis, Shannon Glaser, Lulu Chen, Yuqing Huo, Gianfranco Alpini, Chaodong Wu – 9 January 2018 – Adenosine 2A receptor (A2AR) exerts protective roles in endotoxin‐ and/or ischemia‐induced tissue damage. However, the role for A2AR in nonalcoholic fatty liver disease (NAFLD) remains largely unknown.

Hepatitis E virus replication and interferon responses in human placental cells

Leonard Knegendorf, Svenja A. Drave, Viet Loan Dao Thi, Yannick Debing, Richard J. P. Brown, Florian W. R. Vondran, Kathrin Resner, Martina Friesland, Tanvi Khera, Michael Engelmann, Birgit Bremer, Heiner Wedemeyer, Patrick Behrendt, Johan Neyts, Thomas Pietschmann, Daniel Todt, Eike Steinmann – 8 January 2018 – Hepatitis E virus (HEV) is a member of the genus Orthohepevirus in the family Hepeviridae and the causative agent of hepatitis E in humans. HEV is a major health problem in developing countries, causing mortality rates up to 25% in pregnant women.

Subscribe to